TITLE

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure

PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding comparison of drugs carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure, published in the 2003 issue of the journal "Lancet." Patients were allocated to twice-daily target doses of carvedilol or metoprolol. Main outcome measures all-cause mortality, cardiovascular mortality, the composite endpoint of all-cause mortality or all-cause admission and adverse events. Patients who received carvedilol had lower risks for all-cause mortality and cardiovascular mortality than did those who received metoprolol tartrate.
ACCESSION #
12104530

 

Related Articles

  • Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure: COMMENTARY. Furberg, Curt D.; Psaty, Bruce M. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p5 

    This article focuses on a study regarding comparison of drugs carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure, published in the 2003 issue of the journal "Lancet." The treatment of chronic heart failure is a crowded field with multiple choices, both between...

  • Achieving optimal beta1-blockade with metoprolol CR/Zok. Wikstrand, J. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI46 

    The metoprolol CR/Zok is a multi-unit formulation containing metoprolol succinate controlled release (CR/Zok) in the form of individual drug delivery units (microcapsules). Each microcapsule acts as a diffusion cell and is designed to deliver metoprolol succinate at a near constant rate for...

  • Prescription drugs uses and effects. Gallimore, David; Jordan, Sue // Nursing Standard;7/21/2004, Vol. 18 Issue 45, preceding p3 

    Provides information about angiotensin-converting enzyme inhibitors used for treating cardiovascular diseases. Indications; Administration; Contraindications; Drug interactions.

  • Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. O'Dell, Kate M.; Kalus, James S.; Kucukarslan, Suzan; Czerska, Barbara // American Journal of Health-System Pharmacy;3/15/2005, Vol. 62 Issue 6, p606 

    Purpose. The impact of adding nesiritide to standard therapy and positive inotropic agents in patients with end-stage heart failure and secondary pulmonary hypertension (PH) was studied. Methods. Patients included in this retrospective study were 18 years of age or older, admitted to the...

  • Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure. Furberg, Curt D.; Psaty, Bruce M. // Evidence Based Medicine;Jan/Feb2004, Vol. 9 Issue 1, p14 

    The article presents a study analyzing the effectiveness for lowering mortality in chronic heart failure. Researchers observed that patients who received carvediol had lower risks of all cause mortality and cardiovascular mortality than did those who received metoprolol tartrate. However, the...

  • Carvedilol and Metoprolol European Trial:Do the results merit challenge? Smith, Karen M.; Dombrowski, Robert C. // American Journal of Health-System Pharmacy;6/15/2004, Vol. 61 Issue 12, p1289 

    Comments on the results of the Carvedilol or Metroprolol European Trial (COMET), which attempted to determine whether differences in outcomes exist between carvedilol and metoprolol tartrate in congestive heart failure (CHF) patients. Indication that carvedilol reduces mortality more than...

  • Drug-Drug Interactions of β-Adrenoceptor Blockers. Brodde, Otto-Erich; Kroemer, Heyo K. // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Dec2003, Vol. 53 Issue 12, p814 

    Patients with cardiovascular diseases are often treated by concurrent multiple drug therapy. It is therefore plausible that with an increasing number of drugs the risk of drug interactions increases. Such interactions can be either pharmacodynamic (and are due to the mechanism of the ad-...

  • isosorbide dinitrate.  // Royal Society of Medicine: Medicines;2002, p311 

    The article presents information on isosorbide dinitrate, a short-acting vasodilator and anti-angina drug. It is used to prevent attacks of angina pectoris (ischaemic heart pain), for instance when taken before exercise for symptomatic relief during an acute attack, and as an adjunct (to aid and...

  • Very low LDL targets lead to other risks.  // GP: General Practitioner;6/9/2006, p6 

    The article reports that the aggressive cholesterol targets set for the primary prevention of cardiovascular disease could see most adults taking statins. The U.S. researchers said that U.S. guidelines to lower low-density lipoprotein cholesterol to below 1.81mmol/l in high-risk individuals...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics